RELEReleases

Scaling Complex Peptide Conjugates: BioDuro Hosts Technical Webinar

With approximately 300 peptide-drug conjugates currently in clinical development, the demand for refined synthesis strategies has reached a critical threshold. BioDuro’s Dr. Yuyan Chen will address these technical hurdles during an upcoming Xtalks webinar on October 30, 2026, focusing on the path from initial design to large-scale production.

Bio & NewsOctober 14, 2026774 reads0

The current therapeutic landscape is shifting toward increasingly intricate molecular structures. Practitioners now face distinct challenges when navigating the synthesis of radionuclide-drug conjugates, peptide-oligonucleotide conjugates, and antibody-peptide conjugates. These modalities require precise control over peptide structure, linker integrity, and payload attachment, each of which dictates the success of the final clinical product.

During the session, Dr. Chen will examine how route selection and downstream processing influence project timelines and purity standards. By utilizing specific case studies, the presentation will illustrate the intersection of peptide synthesis with DNA-encoded libraries and early-stage chemistry, manufacturing, and controls. The event provides a framework for researchers to align their analytical methods with the evolving requirements of complex conjugate development.

Comments (0)

Leave a comment

No comments yet. Be the first!